ANCA-associated vasculitis

AR Kitching, HJ Anders, N Basu, E Brouwer… - Nature reviews Disease …, 2020 - nature.com
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a
group of disorders involving severe, systemic, small-vessel vasculitis and are characterized …

B cells, antibodies, and more

W Hoffman, FG Lakkis, G Chalasani - Clinical Journal of the …, 2016 - journals.lww.com
B cells play a central role in the immunopathogenesis of glomerulonephritides and
transplant rejection. B cells secrete antibodies that contribute to tissue injury via multiple …

ANCA glomerulonephritis and vasculitis

JC Jennette, PH Nachman - … Journal of the American Society of …, 2017 - journals.lww.com
ANCA vasculitis has an associated autoimmune response that produces ANCAs that induce
distinct pathologic lesions. Pauci-immune necrotizing and crescentic GN is a frequent …

ANCA-associated vasculitis: an update

S Almaani, LA Fussner, S Brodsky, AS Meara… - Journal of clinical …, 2021 - mdpi.com
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group
of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …

Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease

JC Jennette, RJ Falk - Nature Reviews Rheumatology, 2014 - nature.com
Antineutrophil cytoplasmic autoantibodies (ANCAs) are the probable cause of a distinct form
of vasculitis that can be accompanied by necrotizing granulomatosis. Clinical and …

Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology

F Fagni, F Bello, G Emmi - Frontiers in Medicine, 2021 - frontiersin.org
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare multisystemic disease
classified both amongst hypereosinophilic disorders and ANCA-associated vasculitis …

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

SP McAdoo, N Medjeral-Thomas… - Nephrology Dialysis …, 2019 - academic.oup.com
Background Current guidelines advise that rituximab or cyclophosphamide should be used
for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA) …

Effector and regulatory B cells in immune-mediated kidney disease

K Oleinika, C Mauri, AD Salama - Nature Reviews Nephrology, 2019 - nature.com
B cells have a central role in many autoimmune diseases, including in those with renal
involvement, as well as in the immunological response to kidney transplantation. The …

Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis

F Alberici, RM Smith, RB Jones, DM Roberts… - …, 2015 - academic.oup.com
Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course.
Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes …

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis

WF Pendergraft III, FB Cortazar, J Wenger… - Clinical Journal of the …, 2014 - journals.lww.com
Results In the study, 172 patients (mean age= 60 years, 55% women, 57% myeloperoxidase–
ANCA) treated from April of 2006 to March of 2013 underwent continuous B-cell depletion …